Please use this identifier to cite or link to this item:
Title: Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma
Authors: Kumar P.
Nandi S.
Tan T.Z. 
Ler S.G.
Chia K.S. 
Lim W.-Y.
Bütow Z.
Vordos D.
De laTaille A.
Al-Haddawi M.
Raida M.
Beyer B.
Ricci E.
Colombel M.
Chong T.W.
Chiong E.
Soo R.
Park M.K.
Ha H.K.
Gunaratne J.
Thiery J.P.
Keywords: apolipoprotein A4
coronin 1A
DJ 1 protein
gamma synuclein
peptides and proteins
semenogelin 2
unclassified drug
tumor marker
bladder biopsy
bladder carcinoma
cohort analysis
controlled study
diagnostic accuracy
diagnostic test accuracy study
enzyme linked immunosorbent assay
human cell
human tissue
major clinical study
mass spectrometry
predictive value
protein expression
receiver operating characteristic
reverse transcription polymerase chain reaction
sensitivity and specificity
transitional cell carcinoma
validation study
Western blotting
Carcinoma, Transitional Cell
case control study
tumor recurrence
Urinary Bladder Neoplasms
Biomarkers, Tumor
Carcinoma, Transitional Cell
Case-Control Studies
Cohort Studies
Neoplasm Recurrence, Local
Reproducibility of Results
Sensitivity and Specificity
Urinary Bladder Neoplasms
Issue Date: 2015
Publisher: Impact Journals LLC
Citation: Kumar P., Nandi S., Tan T.Z., Ler S.G., Chia K.S., Lim W.-Y., Bütow Z., Vordos D., De laTaille A., Al-Haddawi M., Raida M., Beyer B., Ricci E., Colombel M., Chong T.W., Chiong E., Soo R., Park M.K., Ha H.K., Gunaratne J., Thiery J.P. (2015). Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget 6 (15) : 13539-13549. ScholarBank@NUS Repository.
Abstract: Transitional bladder carcinoma (BCa) is prevalent in developed countries, particularly among men. Given that these tumors frequently recur or progress, the early detection and subsequent monitoring of BCa at different stages is critical. Current BCa diagnostic biomarkers are not sufficiently sensitive for substituting or complementing invasive cystoscopy. Here, we sought to identify a robust set of urine biomarkers for BCa detection. Using a high-resolution, mass spectrometry-based, quantitative proteomics approach, we measured, compared and validated protein variations in 451 voided urine samples from healthy subjects, non-bladder cancer patients and patients with non-invasive and invasive BCa. We identified five robust biomarkers: Coronin-1A, Apolipoprotein A4, Semenogelin-2, Gamma synuclein and DJ-1/PARK7. In diagnosing Ta/T1 BCa, these biomarkers achieved an AUC of 0.92 and 0.98, respectively, using ELISA and western blot data (sensitivity, 79.2% and 93.9%; specificity, 100% and 96.7%, respectively). In diagnosing T2/T3 BCa, an AUC of 0.94 and 1.0 was attained (sensitivity, 86.4% and 100%; specificity, 100%) using the same methods. Thus, our multiplex biomarker panel offers unprecedented accuracy for the diagnosis of BCa patients and provides the prospect for a non-invasive way to detect bladder cancer.
Source Title: Oncotarget
ISSN: 19492553
DOI: 10.18632/oncotarget.3841
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_3841.pdf3.24 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.